Market Overview

Linical and Accelovance Unite Under Linical Name and Appoint New CEO

Share:

Linical
and Accelovance
recently merged
to create a leading midsized, global contract research organization
(CRO) with a significant footprint across North America, Europe and
Asia-Pacific. As the next step in the merger, Accelovance has
incorporated Linical into its name and will operate as Linical
Accelovance Group, which includes Linical Accelovance America, Europe,
Romania and China. Additionally, Vita
M. Lanoce, M.S
., has been appointed as chief executive officer of
Linical Accelovance Group.

Lanoce, previously chief operating officer at Accelovance, has more than
22 years of experience in clinical research at companies including
Covance, Synexus (formerly Radiant Research) and Bristol-Myers Squibb.
In her new role, Lanoce will oversee all business activities for the
Linical Accelovance Group.

"The name change is the next step for us to work collaboratively under a
shared vision of quality, success, innovation and communication," said
Lanoce. "I look forward to ensuring the continued delivery of robust
solutions and personal service, and guiding our collective strengths for
enhanced service offerings."

Comprising approximately 925 people across more than 20 countries,
Linical is the ideal midsized, global CRO partner for drug developers
looking to expand their programs into new markets. The company offers
the same reach and experience as larger CROs, yet maintains a
personalized, hands-on service approach. The new combined company is
capable of conducting studies from early-phase research through
large-scale, multinational and late-phase trials.

As a one-stop provider for clinical development programs, Linical offers
a full scope of flexible solutions and a wide range of therapeutic
expertise with specializations in dermatology, immunology, neurology,
oncology and vaccines. Linical also demonstrates its oncology expertise
through its HERO™
Project
, which combines its scientific expertise and site networks
to accelerate oncology therapeutics to market. Additionally, Linical's
patient engagement solutions are clinical research-focused, enhancing
patient recruitment, retention, compliance, surveillance and safety data
collection.

About Linical
Linical, a global, midsized contract research
organization with a significant footprint across North America, Europe
and Asia-Pacific, is the ideal partner for drug developers looking to
expand their program into new markets. With operations in more than 20
countries, our global reach makes us uniquely capable of conducting
large-scale, multinational studies. At Linical, we deliver a
personalized, high-touch service approach across a variety of
therapeutic areas and in all phases of development. For more
information, visit Linical.cojp/en/
or Accelovance.com.

View Comments and Join the Discussion!